01:06 , Jan 8, 2019 |  BC Innovations  |  Distillery Therapeutics

Transplant

INDICATION: Heart transplant rejection; graft rejection Mouse studies suggest inhibiting CORO1A or its downstream mediator PDE-4 could help treat heart transplant and skin graft rejection. In a mouse model of heart transplantation, systemic CORO1A knockout...
15:21 , Mar 21, 2017 |  BC Innovations  |  Distillery Therapeutics

Pulmonary

INDICATION: Chronic obstructive pulmonary disease (COPD) In vitro and cell culture studies identified a dual-acting PDE-4 inhibitor/ ADRB2 agonist that could help treat COPD. In in vitro activity assays, a quinolone analog conjugated to a...
07:00 , May 30, 2016 |  BioCentury  |  Strategy

Taking Takeda global

Two years after joining Takeda Pharmaceutical Co. Ltd. , Christophe Weber has narrowed the company's therapeutic focus, expanded the executive team and reorganized its approach to market with the aim of transforming the company into...
08:00 , Dec 21, 2015 |  BC Week In Review  |  Company News

Takeda, AstraZeneca deal

AstraZeneca will acquire Takeda’s core respiratory business, including Daliresp roflumilast, Alvesco ciclesonide, Omnaris ciclesonide nasal spray and seven undisclosed early pipeline products. Takeda will receive a $575 million upfront payment and will transfer about 200...
02:33 , Dec 17, 2015 |  BC Extra  |  Top Story

AZ bulks up China operations, respiratory portfolio

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Wednesday it would build up its presence in China and acquire a global respiratory portfolio from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) for $575 million in cash. AZ's growth in China...
08:00 , Feb 23, 2015 |  BC Week In Review  |  Clinical News

Daliresp roflumilast: Phase III/IV data

The 1-year, double-blind, international Phase III/IV REACT trial in 1,945 patients showed that 500 µg daily oral Daxas plus a long-acting beta 2 agonist (LABA) and an inhaled corticosteroid (ICS) with or without a long-acting...
08:00 , Feb 9, 2015 |  BC Week In Review  |  Company News

Actavis, AstraZeneca deal

AstraZeneca will acquire U.S. and Canadian rights to Actavis’ branded respiratory portfolio in a deal slated to close this quarter. Actavis will receive an upfront payment of $600 million and will be eligible for low...
02:13 , Feb 6, 2015 |  BC Extra  |  Company News

AZ acquires rights to Actavis' COPD drugs

AstraZeneca plc (LSE:AZN; NYSE:AZN) obtained rights in the U.S. and Canada to the respiratory franchise of Actavis plc (NYSE:ACT). AZ will pay Actavis $600 million up front in the deal, plus a $100 million payment...
07:00 , Oct 13, 2014 |  BioCentury  |  Strategy

Streamlining Takeda's Profit Story

After spending a decade growing the company via acquisition, Takeda Pharmaceutical Co. Ltd. is now focused on getting its costs in line with its global pharma peers. But to grow EPS in line with Street...
07:00 , Mar 20, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Renal disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Renal disease Renal disease Phosphodiesterase-4 (PDE-4) Rat and in silico studies suggest blocking PDE-4 inhibition could help treat kidney disease by sustaining podocyte differentiation. In glomeruli...